Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form.
New methods of manufacture have enabled the creation of novel dosage forms with unique rapid-dispersion properties. This study combines one such technique with a statistical experimental design to develop dosage forms from captopril, an angiotensin-converting enzyme inhibitor used to treat cases of hypertensive emergency. The TheriForm process, a novel microfabrication technique, was used to build the dosage forms in a layer-by-layer fashion. Three key formulation factors were chosen for the design of experiments. A modified central composite design (Box-Behnken design) was used to maximize the efficiency of the experiments. A total of 13 distinct formulations were fabricated and tested, using mannitol as the bulk excipient. In addition, three replicates of the center point were tested to assess variability and experimental error. These formulations were tested for speed of dispersion (flash time), active content, hardness, friability, and moisture absorption. Regression analysis was performed to fit data responses to quadratic equations. Excellent dose accuracy (95% to 102% of target) and content uniformity (between 1.03% to 2.84%) were observed from all experimental formulation batches. As expected, the choice of powder additive (maltitol, maltodextrin, polyvinyl pyrrolidone), level of additive (2.5% to 7.5%), and saturation level of the binder liquid (45% to 65%) were all found to be significant factors for the TheriForm process. The regression analysis suggested that a rapidly dispersing dosage form of optimal physical properties would be obtained when a powder mixture of mannitol (97.5%) and maltitol (2.5%) is used at a saturation level of 45%. In conclusion, rapidly dispersing captopril oral dosage forms were successfully fabricated and tested. A wide range of physical properties, flash time, and hardness, were determined experimentally, and the effects of key formulation factors were identified.
Lee
Kyoung-Jin
KJ
Locus Discovery, Blue Bell, Pennsylvania, USA.
Kang
Anthony
A
Delfino
John J
JJ
West
Thomas G
TG
Chetty
Dushen
D
Monkhouse
Donald C
DC
Yoo
Jaedeok
J
D000284:Administration, Oral; D002216:Captopril / Q000138:chemical synthesis*; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D013678:Technology, Pharmaceutical / Q000295:instrumentation / Q000379:methods*
D004304:Dosage Forms; D002216:Captopril